Medical Devices

Micro-Tech Endoscopy brings key GI products in-house as CONMED exits the market. The move ensures clinician access and strengthens Micro-Tech’s global position.

With a major Series B financing, Crossbow advances its TCR-mimetic therapies, aiming to unlock a new frontier in the fight against a broad range of cancers.

JenaValve's Trilogy system gains historic FDA approval, offering a new, minimally invasive option for high-risk patients with a life-threatening heart condition.

CareCloud unveils its next-gen MAP App, blending AI with trusted HFMA benchmarks to help hospitals navigate complex financial challenges and boost efficiency.

Swiss firm H55's flight-proven batteries are fast-tracking a new hybrid-electric regional aircraft demonstrator, promising a 30% leap in fuel efficiency.

Artelo Biosciences is testing a novel cannabinoid drug for glaucoma, aiming to protect vision in a way current treatments can't—all without diluting shares.

A new partnership will leverage genetically engineered mice to create novel antibody drugs, potentially unlocking treatments for cancer and brain diseases.

A new AI-powered blood test for early liver cancer detection is now accessible nationwide through Quest Diagnostics, aiming to improve dismal screening rates.

ACTO's new AI suite automates workflows, promising to boost efficiency and compliance for pharma and medtech field professionals while keeping humans in control.

InflaRx announces a late-breaking presentation on its Phase 3 trial for vilobelimab, offering potential new hope for pyoderma gangrenosum patients.

With a new CEO and Chair, IsomAb is advancing a disease-modifying drug for 9 million angina patients, eyeing a major Series A fundraise.

New preclinical data reveals a novel gene therapy that not only kills tumor cells but also boosts immunity, offering hope against drug-resistant lung cancer.

Student innovators unveil an AI lifeline for ICUs at Quest Global's Ingenium, tackling a critical medical crisis and showcasing India's engineering future.

A novel drug mimicking exercise aims to solve a major problem with today's weight-loss meds: muscle loss. Atrogi's ATR-258 has entered a key human trial.

The deal, part of a broader consolidation strategy by parent The Lockwood Group, aims to meet rising pharma demand for advanced data and patient services.

With late-breaking hypertension data and an AI-driven platform, Kardigan is set to showcase a new, personalized approach to cardiovascular medicine.

A new strategic partnership aims to unite California's life science hubs, creating a streamlined path to capital for medtech and biotech startups.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

A century-old cardiology group is expanding advanced heart care in the Mid-South by partnering with Atria Health, challenging the trend of hospital buyouts.

Belgian firm Endo Tools Therapeutics wins US approval for its next-gen endomina® EZFuse, a device promising to cut GI procedure times by up to 50%.